The global Huntington’s disease treatment market was estimated to be worth USD 345 million in 2021. The market is likely to grow at a rate of 16.0% in the forecast period of 2023-2031. Driven by the growing demand and increasing R&D activities, the market is anticipated to be worth USD 1440 million by 2030.
Huntington’s disease is a rare genetic disorder that causes the gradual degeneration of nerve cells in the brain. Depending on the time of the onset, the disease is of two types, juvenile and adult Huntington’s disease.
Huntington’s disease possesses a wide array of signs and symptoms including impairing muscular movements, altered functional abilities, other psychiatric and cognitive disorders. Certain kinds of behavioural and physical changes are also prevalent in juvenile Huntington’s disease.
Huntington’s disease is an autosomal dominant disorder, and hence can be caused by a single copy of the parent’s non-typical gene. Henceforth, every child has a probability of 50 per cent of inheriting the disease-causing gene.
The diagnosis of Huntington’s disease follows a defined procedure of various diagnostic tests and scans. Neurological examination, neuropsychological testing, psychiatric evaluation, brain imaging and function tests, genetic counselling and testing, and predictive genetic test are some of the diagnostic assessments used to confirm the presence of Huntington’s disease.
The treatment for Huntington’s disease is based on the symptoms management and medications are being prescribed depending on the clinical manifestations of the disease. Medications for movement and psychiatric disorders, and other different therapies, such as physical therapy, speech therapy, psychotherapy, and occupational therapy have been found effective in the treatment of Huntington’s disease.
The Huntington’s disease treatment market can be categorised into the following segments:
Market Breakup by Treatment Method
Market Breakup by Diagnosis Method
Market Breakup by Drug Class
Huntington’s Disease Treatment Market Breakup by Treatment Channel
Market Breakup by Region
The Huntington’s disease treatment market is primarily driven by the rising incidence and prevalence of Huntington’s disease. The disease has an approximate prevalence of 5.8 per 100,000 people, thus attributing to the increased demand for the diagnosis and treatment of Huntington’s disease.
Besides, the growth of the market is driven by the rising adoption of improved medical therapies to meet the demand of the growing patient pool. For example, alternative treatment options such as psychotherapy, speech therapy, physiotherapy, and occupational therapy have impacted the market growth positively.
Further, the market is expected to expand due to the increasing research and developmental activities in the diagnosis and therapeutics sector. Certain government initiatives have also supported the development of novel drugs, thus accelerating the market growth forward during the forecast period.
North America is anticipated to hold the largest share of the market owing to the higher disease prevalence, advanced healthcare infrastructure, technological advancements, and increased awareness.
The Asia Pacific region is projected to witness the fastest growth during the forecast period. The growing prevalence of Huntington’s disease in developing countries, supporting government measures, and rising product penetration have attributed to this region’s Huntington’s disease treatment market growth.
There is no approved treatment regimen for the complete eradication of Huntington’s disease. However, different classes of medications are used for the management of psychiatric, motor, and other associated symptoms. The medications prescribed are solely based on the clinical manifestations of the patient and can evolve over the course of the disease.
The medications used for controlling impaired movements are deutetrabenazine and tetrabenazine. Certain antipsychotic drugs, such as olanzapine, fluphenazine, and haloperidol have been found beneficial in movement disorders. Other drugs such as amantadine, clonazepam, and levetiracetam are also used for the treatment of chorea.
The medications used for managing psychiatric disorders are antidepressants, antipsychotics, and anticonvulsants. Antidepressants include drugs such as sertraline, citalopram, fluoxetine, and escitalopram. Quetiapine and olanzapine are some of the commonly used antipsychotic drugs for suppressing extreme mood swings, violent outbursts, and other symptoms. Anticonvulsants such as lamotrigine, carbamazepine, and Divalproex are mood-stabilising drugs used to manage the highs and lows of bipolar disorder.
Other alternative therapeutic options include the incorporation of several therapies such as physical therapy, speech therapy, psychotherapy, and occupational therapy. These therapies have exhibited promising prospects in the treatment of Huntington’s disease. Certain kinds of changes in lifestyle and nutrition habits also help in coping with this disease.
With extensive research and development, scientists are effortlessly working on developing novel therapeutic agents that could help in the treatment of Huntington’s disease. Many drugs are being discovered and under different phases of clinical trials for assessing their safety, efficacy, tolerability, and pharmacokinetics.
Roche, a key market player, has discovered an HTT-lowering drug, Tominersen, for adults that are in Phase III clinical trials. The drug has shown potential efficacy and tolerability in lowering the disease burden of adults and juveniles.
Wave Life Sciences has discovered a novel drug product WVE-003, that targets SNP and have better therapeutic efficacy and lesser side effects. This drug is in the initial phases of clinical trials and requires detailed assessment and observation.
Novartis and PTC Therapeutics have collaboratively initiated the clinical trials for the drug modulators PTC518 and branaplam, which are anticipated to slow down the progression of Huntington’s disease.
Uniqure has recently developed a gene therapy, AMT-130, that is being assessed under the Phase I and Phase II clinical trials. This therapy targets the huntingtin-ex1 and full-length hungitin, responsible for causing Huntington’s disease.
All the discovered treatment approaches are based on the aim of reducing the huntingtin levels and subsequently will help in treating Huntington’s disease. Several ongoing clinical trials are emerging as key trends, which are likely to bolster the growth of Huntington’s disease treatment market.
The report gives an in-depth analysis of the key players involved in Huntington’s disease treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Treatment Method||
|Breakup by Diagnosis Method||
|Breakup by Drug Class||
|Breakup by Treatment Channel||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Huntington’s Disease Overview
4.1 Guidelines and Stages
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials
6.2 Patent Landscape
6.2.1 Patent Overview
18.104.22.168 Patent Status and Expiry
22.214.171.124 Timelines from Drug Development to Commercial Launch
126.96.36.199 New Drug Application
188.8.131.52.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
184.108.40.206 US FDA
220.127.116.11 EU EMA
18.104.22.168 INDIA CDSCO
22.214.171.124 JAPAN PMDA
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Global Huntington’s Disease Treatment Market
8.1 Global Huntington’s Disease Treatment Market Overview
8.2 Global Huntington’s Disease Treatment Market Analysis
8.2.1 Market Overview
126.96.36.199 Global Huntington’s Disease Treatment Market Historical Value (2016-2022)
188.8.131.52 Global Huntington’s Disease Treatment Market Forecast Value (2023-2031)
8.2.2 Global Huntington’s Disease Treatment Market by Treatment Method
184.108.40.206 Market Overview
220.127.116.11.1 Symptomatic Treatment
18.104.22.168.2 Disease-modifying Therapies
22.214.171.124.3 Palliative Care Treatment
8.2.3 Global Huntington’s Disease Treatment Market by Diagnosis Method
126.96.36.199 Market Overview
188.8.131.52.1 Neurological and Neuropsychological Tests
184.108.40.206.2 Psychiatric Evaluation
220.127.116.11.3 Brain-Imaging and Function Tests
18.104.22.168.4 Genetic Counselling
22.214.171.124.5 Predictive Genetic Tests
8.2.4 Global Huntington’s Disease Treatment Market by Drug Class
126.96.36.199 Market Overview
188.8.131.52.1 Mood Stabilizers
184.108.40.206.2 Antipsychotic Drugs
8.2.5 Global Huntington’s Disease Treatment Market by Treatment Channel
220.127.116.11 Market Overview
8.2.6 Global Huntington’s Disease Treatment Market by Region
18.104.22.168 Market Overview
22.214.171.124.1 North America
126.96.36.199.3 Asia Pacific
188.8.131.52.4 Middle East and Africa
184.108.40.206.5 Latin America
9 North America Huntington’s Disease Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe Huntington’s Disease Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
11 Asia Pacific Huntington’s Disease Treatment Market
11.1 Market Share by Country
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
12 Latin America Huntington’s Disease Treatment Market
12.1 Market Share by Country
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
13 Middle East and Africa Huntington’s Disease Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
14 Global Huntington’s Disease Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives & Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 H. Lundbeck A/S
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.2 Teva Pharmaceutical Industries Ltd.
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.3 Bausch Health Companies Inc.
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.4 Hetero Drugs Limited
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.5 Lupin Limited
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.6 Hikma Pharmaceuticals plc
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.7 Dr. Reddy’s Laboratories Ltd
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.8 Sun Pharmaceutical Industries Limited
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.9 SOM Biotech
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.10 Annexon, Inc.
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
16 Global Huntington’s Disease Treatment Market- Distribution Model (Additional Insight)
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
The market is primarily driven by the rising cases of Huntington’s disease, increasing research and developmental activities and novel product launches and approvals.
Based on the drug class, the market is categorised into mood stabilizers, antipsychotic drugs, antidepressants, and others.
Based on the diagnosis method, the market is segmented into neurological exams and neuropsychological tests, psychiatric evaluation, brain-imaging and function tests, genetic counselling, predictive genetic tests, and others.
Based on the treatment method, the market is bifurcated into symptomatic treatment, disease-modifying therapies, and palliative care treatment, among others.
Based on the treatment channel, the market is divided into public and private.
The different regions in the market are North America, Europe, Asia Pacific, Latin America the Middle East and Africa. North America is anticipated to hold a largest share of the market during the forecast period.
The key companies involved in the market are H. Lundbeck A/S, Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Hetero Drugs Limited, Lupin Limited, Hikma Pharmaceuticals plc, Dr. Reddy’s Laboratories Ltd, Sun Pharmaceutical Industries Limited, SOM Biotech, and Annexon, Inc., among others.
Single User License
Five User License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.